Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

NanoViricides Gelecekteki Büyüme

Future kriter kontrolleri 0/6

NanoViricides kazanç ve gelirinin sırasıyla yıllık 14.2% ve 61% oranında artması tahmin edilirken, EPS'nin yıllık 21.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

14.2%

Kazanç büyüme oranı

21.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.7%
Gelir büyüme oranı	61.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	10 Jul 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

Kazanç ve Gelir Büyüme Tahminleri

NYSEAM:NNVC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	7	-6	-4	-4	1
6/30/2026	3	-8	-5	-5	1
6/30/2025	N/A	-15	-9	-8	2
6/30/2024	N/A	-8	-6	-6	N/A
3/31/2024	N/A	-10	-6	-6	N/A
12/31/2023	N/A	-9	-6	-6	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-9	-6	-6	N/A
3/31/2023	N/A	-7	-6	-6	N/A
12/31/2022	N/A	-7	-6	-5	N/A
9/30/2022	N/A	-7	-7	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-9	-7	-7	N/A
6/30/2021	N/A	-9	-8	-8	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-15	-9	-9	N/A
9/30/2020	N/A	-14	-8	-7	N/A
6/30/2020	N/A	-13	-7	-7	N/A
3/31/2020	N/A	-14	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-7	-7	N/A
3/31/2019	N/A	-8	-9	-9	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-9	-8	-8	N/A
3/31/2018	N/A	-9	N/A	-5	N/A
12/31/2017	N/A	-10	N/A	-6	N/A
9/30/2017	N/A	-9	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-7	N/A
12/31/2015	N/A	-5	N/A	-6	N/A
9/30/2015	N/A	-4	N/A	-6	N/A
6/30/2015	N/A	-2	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-6	N/A
9/30/2014	N/A	-6	N/A	-7	N/A
6/30/2014	N/A	-14	N/A	-6	N/A
3/31/2014	N/A	-9	N/A	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NNVC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: NNVC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: NNVC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: NNVC gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: NNVC gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NNVC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

NanoViricides Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 38% to US$5.25

Recent updates

NanoViricides, Inc. Continues Its March Towards a Phase II Clinical Trial of NV-387

NanoViricides, Inc. Provides an Update on Its Clinical Program and Strategy NV-387

NanoViricides, Inc. Announces Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virusilling, Technology Platform Intending to Revolutionize Treatment of Viral Infections

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin